Cynata Therapeutics has lodged a replacement prospectus for a fully underwritten $913,000 entitlement offer, with the cash earmarked largely for adviser costs, intellectual property maintenance and working capital. The raising gives the biotech a near-term funding bridge, but the prospectus again flags a material uncertainty over its ability to continue as a going concern.
- 3-for-8 renounceable entitlement offer at $0.01 per share
- Approximately 91.3 million new shares and 30.4 million free attaching options
- 18 million unquoted options for underwriter Caravel Securities
- Pro forma cash rises to approximately $1.30 million after the offer
- Further funding may be required to pursue new assets or develop Cymerus
Replacement prospectus clarifies $913,000 capital raising
Cynata Therapeutics Limited (ASX:CYP) has replaced its 8 October prospectus with a revised document for a $913,000 entitlement offer, a modest raise whose importance lies less in its size than in the company’s limited room to manoeuvre. Eligible shareholders will be offered three new shares for every eight held at $0.01 each, with one free unquoted option for every three new shares issued.
The revised prospectus adds detail on the use of funds, confirms that no related party will act as a sub-underwriter or receive shortfall securities, and corrects an error in the pro forma financial information. The offer is fully underwritten by Caravel Securities, while the earlier entitlement offer had already framed the raise as a short-term funding measure after Cynata’s recent clinical setbacks.
Cash buys time while Cynata reassesses Cymerus
Cynata expects to issue about 91.3 million new shares, taking shares on issue from 243.5 million to approximately 334.7 million if the offer is completed in full. The $0.01 issue price represented a 9.1% discount to the 7 October closing price of $0.011. Shareholders who do not participate will be diluted, with the prospectus showing a holding of 10 million shares falling from 4.11% to 2.99% on completion under its example.
The company’s stated plan is no longer centred on pressing ahead with the two major programs that produced disappointing June results. The board says it is evaluating development pathways for the Cymerus platform, which manufactures mesenchymal stromal cells from a single cell source, while also considering opportunities to realise value from that technology and obtain rights to new assets. The prospectus says CYP-001 in kidney transplantation remains under evaluation in a Phase 1/2 trial being conducted and funded by Leiden University Medical Center.
Of the combined $1.449 million in cash available in the prospectus funding table, $300,000 is allocated to director and consultant costs, $250,000 to legal, patent and professional adviser fees, and $300,129 to general working capital. A further $150,000 is earmarked for maintaining existing intellectual property and cell lines. Estimated offer costs of $149,166 mean the gross raise will not translate dollar-for-dollar into operating cash.
Going concern warning and option overhang remain
The financial disclosure is unusually stark for a capital raising of this size. Cynata reports that its FY2026 auditor identified a material uncertainty that may cast significant doubt on its ability to continue as a going concern, while the prospectus says the offer proceeds may not be sufficient to fulfil its strategic objectives. The company also says it is likely to need additional funding, particularly if it secures new development assets.
Participants receive options exercisable at $0.02 for two years and six months after issue, but the options will not trade on ASX. Caravel will receive a further 18 million options on the same terms for underwriting services. If all options issued under the offer are eventually exercised, the prospectus estimates total dilution of 12.64% relative to the post-offer share count, alongside up to $969,000 in exercise proceeds for the company.
The offer is scheduled to close at 5.00pm Melbourne time on 27 October, with results expected on 30 October and the new shares expected to be issued in early November, subject to the stated conditions and ASX quotation. The immediate test is whether the underwritten raise can convert into enough operating time for Cynata to find a viable commercial or partnering pathway for Cymerus before another financing decision comes due.
Bottom Line?
The raise is fully underwritten, but it appears designed to extend limited runway rather than fund a defined clinical development program. The next strategic transaction involving Cymerus may matter more than the offer itself.
Questions in the middle?
- How long will the approximately $1.30 million pro forma cash balance support Cynata’s streamlined operations?
- Can the company secure licensing, partnering or new-asset opportunities on acceptable terms after the recent clinical results?
- Will the underwriter’s sub-underwriting arrangements prevent a concentrated change in control if shareholder participation is weak?